PMV Pharmaceuticals/PMVP

$1.87

-0.26%
-
1D1W1MYTD1YMAX

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein, guardian of the genome, and normal or wild type, p53 has the ability to eliminate cancer cells. The Company’s lead product candidate, PC14586 is designed to bind to the mutation site and structurally correct the misfolded p53 protein, while sparing wild-type p53PC14586 has shown selective on-target activity, which primarily functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition (TGI), and tumor regression as a single agent. The Company has initiated a Phase I/II clinical trial for PC14586. In addition, it is also granted food and drug administration (FDA) Fast Track designation of PC14586 for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

Ticker

PMVP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Mack

Employees

62

Headquarters

Princeton, United States

PMVP Metrics

BasicAdvanced
$95.92M
Market cap
-
P/E ratio
-$1.56
EPS
1.65
Beta
-
Dividend rate

What the Analysts think about PMVP

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 3 analysts.
434.76% upside
High $18.00
Low $5.00
$1.87
Current price
$10.00
Average price target

PMVP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-16.6M
-4.6%
Profit margin
0%
-

PMVP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 19.69%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.42
-$0.38
-$0.34
-$0.31
-
Expected
-$0.46
-$0.48
-$0.45
-$0.39
-$0.39
Surprise
-8.36%
-20%
-23.77%
-19.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell PMV Pharmaceuticals stock

Buy or sell PMV Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing